Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939548 · ClinicalTrials.gov registry record · Phase 2
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT01939548 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 240 participants.
The verdict
NCT01939548, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 from baseline compared to placebo.
Interventions
- DRUG Placebo
- DRUG PF-02545920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01939548
The ClinicalTrials.gov registry entry for NCT01939548 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01939548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01939548 about?
NCT01939548 is a clinical study titled "An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia". This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920...
What is the current status of trial NCT01939548?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2013-10. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01939548?
The interventions under investigation include: Placebo (DRUG), PF-02545920 (DRUG).
Who is sponsoring clinical trial NCT01939548?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.